Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching

Tobacco Control

Volumn 25, Issue 3, 2016, Pages 267-274

  Hatsukami, Dorothy K ^a,b   Severson, Herbert ^c   Anderson, Amanda ^b   Vogel, Rachael Isaksson ^a   Jensen, Joni ^b   Broadbent, Berry ^c   Murphy, Sharon E ^a   Carmella, Steven ^a   Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c OREGON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTAN-1-OL; BIOLOGICAL MARKER; CHEWING GUM; COTININE; GLUCURONIDE; N'-NITROSONORNICOTINE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NITROSAMINE; PYRIDINE DERIVATIVE;

ADULT; ADVERSE EFFECTS; CHEWING GUM; CLINICAL TRIAL; CONSUMER ATTITUDE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MINNESOTA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OREGON; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; TIME FACTOR; TOBACCO USE DISORDER; TREATMENT OUTCOME; URINALYSIS; URINE;

ADMINISTRATION, ORAL; ADULT; BIOMARKERS; CHEWING GUM; CONSUMER BEHAVIOR; COTININE; FEMALE; GLUCURONIDES; HUMANS; MALE; MIDDLE AGED; MINNESOTA; NICOTINE; NICOTINIC AGONISTS; NITROSAMINES; OREGON; PYRIDINES; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TOBACCO, SMOKELESS; TREATMENT OUTCOME; URINALYSIS;

EID: 84964265398     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2014-052080     Document Type: Article

References (40)

1. Fagerstrom KO, Schildt EB. Should the European Union lift the ban on snus? Evidence from the Swedish experience. Addiction 2003;98:1191-5.
2. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003;12:349-59.
3. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004;13:2035-42.
4. Rodu B, Cole P. Tobacco-related mortality. Nature 1994;370:184.
5. Bates C, Fagerstrom K, Jarvis MJ, et al. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control 2003;12:360-7.
6. Ramstrom L, Wikmans T. Mortality attributable to tobacco among men in Sweden and other European countries: an analysis of data in a WHO report. Tob Induc Dis 2014;12:14.
7. Lee PN. The effect on health of switching from cigarettes to snus—a review. Regul Toxicol Pharmacol 2013;66:1-5.
8. Gilljam H, Galanti MR. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. Addiction 2003;98:1183-9.
9. Lund KE, McNeill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res 2010;12:817-22.
10. Scheffels J, Lund KE, McNeill A. Contrasting snus and NRT as methods to quit smoking: an observational study. Harm Reduct J 2012;9:10.
11. Furberg H, Bulik CM, Lerman C, et al. Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control 2005;14:422-4.
12. Tomar SL. Snuff use and smoking in US men—Implications for harm reduction. Am J Prev Med 2002;23:143-9.
13. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control 2006;15:210-14.
14. Rodu B, Phillips CV. Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey. Harm Reduct J 2008;5:18.
15. Kotlyar M, Hertsgaard LA, Lindgren BR, et al. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:91-100.
16. Heatherton TF, Koslowski LT, Frecker RC, et al. The Fagerström Test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
17. Hatsukami DK, Jensen J, Anderson A, et al. Oral tobacco products: preference and effects among smokers. Drug Alcohol Depend 2011;118:230-6.
18. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43:289-94.
19. Hughes JR, Hatsukami DK. The nicotine withdrawal syndrome: a brief review and update. Int J Smoking Cessation 1992;1:21-6.
20. National Cancer Institute. Clearing the air. Quit smoking today: U.S. Department of health & human services. National Institutes of Health, 2011.
21. Hatsukami DK, Zhang Y, O’Connor RJ, et al. Subjective responses to oral tobacco products: scale validation. Nicotine Tob Res 2013;15:1259-64.
22. Westman E, Levin E, Rose J. Smoking while wearing the nicotine patch: Is smoking satisfying or harmful? Clin Res 1992;40:871A.
23. Cappelleri JC, Bushmakin AG, Baker CL, et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addictive Beh 2007;32:912-23.
24. Murphy SE, Link CA, Jensen J, et al. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev 2004;13:1617-23.
25. Scherer G, Engl J, Urban M, et al. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007;47:171-83.
26. Carmella SG, Ming X, Olvera N, et al. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem Res Toxicol 2013;26:1209-17.
27. Yuan JM, Knezevich AD, Wang R, et al. Urinary levels of the tobacco-specific carcinogen N’-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011;32: 1366-71.
28. Sobell LC, Sobell MB. Timeline follow-back. A technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring alcohol consumption. The Humana Press Inc., 1992:41-69.
29. O’Connor RJ, Norton KJ, Bansal-Travers M, et al. US smokers’ reactions to a brief trial of oral nicotine products. Harm Reduct J 2011;8:1.
30. Barrett SP, Campbell ML, Temporale K, et al. The acute effect of Swedish-style snus on cigarette craving and self-administration in male and female smokers. Hum Psychopharmacol 2011;26:58-62.
31. Shiffman S, Gitchell J, Rohay JM, et al. Smokers’ preferences for medicinal nicotine vs smokeless tobacco. Am J Health Behav 2007;31:462-72.
32. Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res 2010;12:179-83.
33. Biener L, Roman AM, Mc Inerney SA, et al. Snus use and rejection in the USA. Tob Control Published Online First: 25 Feb 2014. doi:10.1136/tobaccocontrol-2013-051342
34. McMillen R, Maduka J, Winickoff J. Use of emerging tobacco products in the United States. J Environ Public Health 2012;2012:989474.
35. King BA, Dube SR, Tynan MA. Current tobacco use among adults in the United States: findings from the National Adult Tobacco Survey. Am J Public Health 2012;102:e93-100.
36. Cobb CO, Weaver MF, Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob Control 2010;19:367-73.
37. Blank MD, Eissenberg T. Evaluating oral noncombustible potential-reduced exposure products for smokers. Nicotine Tob Res 2010;12:336-43.
38. Carter LP, Stitzer ML, Henningfield JE, et al. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev 2009;18:3241-62.
39. Henningfield JE, Hatsukami DK, Zeller M, et al. Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend 2011;116:1-7.
40. Harris AC, Tally L, Schmidt CE, et al. Animal models to assess the abuse liability of tobacco products: Effects of smokeless tobacco extracts on intracranial self-stimulation. Drug Alcohol Depend 2015; 147:60-7.